OntologiesncitclassesNCIT:C154276   
JSON document
Autologous AXL-targeted CAR T-cells CCT301-38
http://purl.obolibrary.org/obo/NCIT_C154276

A preparation of genetically modified autologous T-lymphocytes transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) targeting the receptor tyrosine kinase (RTK) AXL, with potential immunomodulatory and antineoplastic activities. After isolation, transduction, and expansion in culture, the CCT301-38 cells are reintroduced into the patient and are activated within the tumor microenvironment (TME) using proprietary Conditionally Active Biologic (CAB) technology. Upon activation, CAB antibodies bind to a proprietary T-cell signaling domain, promoting T-cell recognition and killing of AXL-expressing tumor cells. AXL is a RTK and oncogene that is overexpressed in many cancer types and is involved in the stimulation of tumor cell proliferation.

Exact Synonyms
Autologous Anti-AXL CAR T Cells CCT30138
Autologous AXL-targeted CAR T-cells CCT301-38
Autologous CAR T-cells Targeting AXL CCT301-38
CCT301 38
CCT301-38
CCT30138 CAR T Cells
class Information
code

C154276

Contributing_Source

GDC

Is_Value_For_GDC_Property

Pharmacologic Substance

Maps_To

Autologous AXL-targeted CAR T-cells CCT301-38

NCI_Drug_Dictionary_ID

794160

NCI_META_CUI

CL555277

PDQ_Closed_Trial_Search_ID

794160

PDQ_Open_Trial_Search_ID

794160

Preferred_Name

Autologous AXL-targeted CAR T-cells CCT301-38

Semantic_Type
  • Cell
  • Pharmacologic Substance
class Relations